JP2023103205A5 - - Google Patents

Download PDF

Info

Publication number
JP2023103205A5
JP2023103205A5 JP2023060583A JP2023060583A JP2023103205A5 JP 2023103205 A5 JP2023103205 A5 JP 2023103205A5 JP 2023060583 A JP2023060583 A JP 2023060583A JP 2023060583 A JP2023060583 A JP 2023060583A JP 2023103205 A5 JP2023103205 A5 JP 2023103205A5
Authority
JP
Japan
Prior art keywords
cancer
independently
compound according
butyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023060583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023103205A (ja
Filing date
Publication date
Priority claimed from JP2018567684A external-priority patent/JP7317505B2/ja
Application filed filed Critical
Publication of JP2023103205A publication Critical patent/JP2023103205A/ja
Publication of JP2023103205A5 publication Critical patent/JP2023103205A5/ja
Priority to JP2025116381A priority Critical patent/JP2025148450A/ja
Pending legal-status Critical Current

Links

JP2023060583A 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物 Pending JP2023103205A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116381A JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353735P 2016-06-23 2016-06-23
US62/353,735 2016-06-23
JP2018567684A JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018567684A Division JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116381A Division JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Publications (2)

Publication Number Publication Date
JP2023103205A JP2023103205A (ja) 2023-07-26
JP2023103205A5 true JP2023103205A5 (cg-RX-API-DMAC7.html) 2023-10-18

Family

ID=60675799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018567684A Active JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物
JP2023060583A Pending JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018567684A Active JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Country Status (10)

Country Link
US (4) US10179117B2 (cg-RX-API-DMAC7.html)
EP (2) EP3474903B1 (cg-RX-API-DMAC7.html)
JP (3) JP7317505B2 (cg-RX-API-DMAC7.html)
KR (2) KR102864909B1 (cg-RX-API-DMAC7.html)
CN (2) CN109843339B (cg-RX-API-DMAC7.html)
AU (2) AU2017281364B2 (cg-RX-API-DMAC7.html)
CA (1) CA3028978A1 (cg-RX-API-DMAC7.html)
IL (1) IL263863B (cg-RX-API-DMAC7.html)
SG (1) SG11201811482YA (cg-RX-API-DMAC7.html)
WO (1) WO2017223357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) * 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
CN109982998A (zh) * 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
CN115448856B (zh) * 2022-09-30 2023-09-22 北京师范大学 一种用于靶向PSMA的EuK二聚体化合物、衍生物及其应用
WO2025213026A1 (en) * 2024-04-04 2025-10-09 Lantheus Medical Imaging, Inc. Astatine-211-labelled psma-binding compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2006091796A2 (en) 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
ES2684322T3 (es) * 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
ES2634894T3 (es) * 2008-08-01 2017-09-29 The Johns Hopkins University Agentes de unión a PSMA y usos de los mismos
WO2010032248A2 (en) 2008-09-17 2010-03-25 Yeda Research And Development Co. Ltd. Multifunctional albumin conjugates
AU2009322167B2 (en) * 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
DK2766364T3 (da) 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10140408B2 (en) 2015-09-04 2018-11-27 Qualcomm Incorporated Selectively encrypting content for distribution from a receiver device to a companion device
WO2017070482A2 (en) * 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
SG11201811482YA (en) * 2016-06-23 2019-01-30 Univ Cornell Double targeted constructs to affect tumor kill
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
US11400165B2 (en) 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
KR20210148157A (ko) 2019-04-03 2021-12-07 타베다 세라퓨틱스, 인코포레이티드 Hsp90-결합 접합체 및 이의 제형
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
US12151004B2 (en) 2020-01-31 2024-11-26 University Of Saskatchewan Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
CA3070610A1 (en) 2020-01-31 2021-07-31 Humphrey FONGE Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US20220143228A1 (en) 2020-10-22 2022-05-12 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
TW202233244A (zh) 2020-11-10 2022-09-01 美商健生生物科技公司 巨環化合物及其使用方法
AU2022213825A1 (en) 2021-01-27 2023-09-14 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
GEAP202316335A (en) 2021-02-01 2023-10-10 Bayer Ag Multimeric chelator compounds for use in targeted radiotherapy
MX2023014069A (es) 2021-05-27 2024-03-15 Janssen Biotech Inc Composiciones y métodos para el tratamiento del cáncer de próstata.
WO2023026236A1 (en) 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma radioconjugates and uses thereof
WO2023026235A1 (en) 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
EP4408839A4 (en) 2021-09-29 2025-08-06 Univ Melbourne MACROCYCLE-CONTAINING COMPOUNDS AND THEIR RADIOLABELED COMPLEXES, USED AS LIGANDS IN TARGETED RADIOTHERAPY APPLICATIONS
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
EP4429718A1 (en) 2021-11-09 2024-09-18 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof

Similar Documents

Publication Publication Date Title
JP2017095457A5 (cg-RX-API-DMAC7.html)
JP2019535744A5 (cg-RX-API-DMAC7.html)
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2022071077A5 (cg-RX-API-DMAC7.html)
JP2024543967A5 (cg-RX-API-DMAC7.html)
JP2022547952A5 (cg-RX-API-DMAC7.html)
JP2020517616A5 (cg-RX-API-DMAC7.html)
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2023542066A5 (cg-RX-API-DMAC7.html)
JP2019522054A5 (cg-RX-API-DMAC7.html)
JP2023512039A5 (cg-RX-API-DMAC7.html)
JP2024506612A5 (cg-RX-API-DMAC7.html)
JP2021534168A5 (cg-RX-API-DMAC7.html)
JP2024156779A5 (cg-RX-API-DMAC7.html)
JP2017509682A5 (cg-RX-API-DMAC7.html)
RU2020113749A (ru) Аналоги таиланстатина
JP2014518543A5 (cg-RX-API-DMAC7.html)
JP2020534300A5 (cg-RX-API-DMAC7.html)
JP2021523169A5 (cg-RX-API-DMAC7.html)
JP2009503110A5 (cg-RX-API-DMAC7.html)
JP2017526662A5 (cg-RX-API-DMAC7.html)
JP2024525740A5 (cg-RX-API-DMAC7.html)
JP2023542065A5 (cg-RX-API-DMAC7.html)